ID MOLM-13/DAC AC CVCL_C0WK DR Wikidata; Q114312312 RX PubMed=33669837; CC Population: Japanese. CC Selected for resistance to: ChEBI; CHEBI_50131; 5-aza-2'-deoxycytidine (Decitabine). CC Sequence variation: Gene fusion; HGNC; HGNC:7132; KMT2A + HGNC; HGNC:7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line). CC Sequence variation: Mutation; HGNC; HGNC:3765; FLT3; Unexplicit; Internal tandem duplication (FLT3-ITD); ClinVar=VCV000016270; Zygosity=Unspecified (from parent cell line). CC Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178. DI NCIt; C9154; Adult acute myeloid leukemia DI NCIt; C3247; Myelodysplastic syndrome DI ORDO; Orphanet_519; Acute myeloid leukemia OX NCBI_TaxID=9606; ! Homo sapiens (Human) HI CVCL_2119 ! MOLM-13 SX Male AG 20Y CA Cancer cell line DT Created: 22-09-22; Last updated: 19-12-24; Version: 5 // RX PubMed=33669837; DOI=10.3390/ijms22042076; PMCID=PMC7923013; RA Janotka L., Messingerova L., Simonicova K., Kavcova H., Elefantova K., RA Sulova Z., Breier A.; RT "Changes in apoptotic pathways in MOLM-13 cell lines after induction RT of resistance to hypomethylating agents."; RL Int. J. Mol. Sci. 22:2076.1-2076.24(2021). //